Levetiracetam May Increase Clot Risk for Patients on Blood Thinners, Study Finds

Researchers from the University of Liverpool and the University of Zurich have reported a potential safety consideration linked to levetiracetam, one of the most frequently prescribed antiseizure medications worldwide. The joint investigation, which combined clinical data analysis with pharmacovigilance reporting, identified a signal that suggests an increased risk of an adverse effect in certain patient groups. Levetiracetam, commonly used to manage epilepsy and other seizure disorders, has been regarded as well‑tolerated, making the new finding notable for clinicians and regulators alike.

The study’s authors caution that the observed safety signal requires further validation through larger, prospective trials before any changes to prescribing practices can be recommended. They emphasize the importance of ongoing monitoring and suggest that healthcare providers remain vigilant for the identified risk while continuing to use levetiracetam according to current guidelines. The research adds to the broader effort to ensure the long‑term safety of widely used antiseizure therapies.